InCarda grabs a $42M round to back PoC study for their inhaled cardio drug
San Francisco-based InCarda Therapeutics is taking a big step forward today, unveiling a $42 million B round after getting the company launched on a shoestring …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.